Benzos to Breakthroughs: Bill Burns on Roche's Transformation

 
• By 

Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.

Podcast: Treating Rare Diseases With tRNA

 
• By 

In this episode of the In Vivo podcast Michelle Werner, CEO of Alltrna, discusses using tRNA as a therapeutic modality for rare diseases.

Big Pharma Headcounts: Obesity Leaders Bulk Up As Others Go Lean

 

As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.

How To Create Organizational Readiness for AI

 
• By 

The time is now to prepare your company for AI implementation. Doing so starts with the C-suite.


Combos, New MOAs, And Oral Formulations Of Injectables: Lilly’s Immunology Strategy

 
• By 

In a competitive immunology landscape, Eli Lilly is looking for novel agents, oral formulations of injectables, and combination therapies that can optimize response and expand the patient pool.

Execs On The Move: October 2024

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

A Decade On, How Deep Do Regeneron’s Oncology Foundations Go?

 
• By 

Regeneron’s clinical and commercial oncology leaders talk to In Vivo about making good on the company’s oncology strategy and pushing the commercial accelerator in a post-Sanofi world.

Winning With Partnerships: How To Turn A Three-Decade-Old Biotech Profitable

 
• By 

Since taking on the CEO role at Theratechnologies in 2020, Paul Lévesque has made it his priority to beef up the company’s commercial portfolio and look for partnerships on potentially high-value programs. Now, the Canadian biotech is turning a profit for the first time in many years.


Schrödinger’s Akinsanya On Low-Risk Pipeline Growth And Platform Evolution

 
• By 

Schrödinger has for years discovered drug candidates for other companies and derisked them, testing them in silico using its computational models. Now, it is exploring its own ability to develop drugs in the clinic, starting with low-risk bets. Will the company’s approach succeed where others have failed?

Double Jeopardy: Brightening The Outlook For Women With Rare Liver Disease

 
• By 

Ipsen rare diseases head Jennifer Schranz talks to In Vivo about why women are especially susceptible to a “diagnostic odyssey,” and how the company is working to find and treat female zebras.

From PhD To Unicorn: Mammoth CEO On Pharma Deals and Squishy Biology

 
• By 

Trevor Martin talked to In Vivo about the importance of sharing a strategic vision with partners, the company’s superpower, and how a PhD is the best prep for a startup.

The Anatomy Of Astellas And Poseida's CAR-T Deal

 
• By 

Dealmakers from CAR-T biotech Poseida Therapeutics and Astellas recently sat down with In Vivo to discuss how they reached a $600m deal that combines their technologies and how they plan on moving forward.


Bristol Myers Squibb ASPIREs For Access In LMICs

 

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

Fusion CEO Talks AZ Deal Making And Canada’s Blossoming Biotech Ecosystem

 
• By 

Fusion Pharmaceuticals Inc CEO John Valliant talked to In Vivo about Canadian leadership in radiopharmaceutical innovation, its differentiated approach, and excitement around combination therapies for precision cancer treatments.

Execs On The Move: September 2024

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Combating Stroke Requires Global Health Systems To Take A Giant Step

 
• By 

Health authorities around the world are being advised to mitigate the relentless rise in the long-term costs of stroke, set to top $1.5tn within a generation. Wider availability of mechanical thrombectomy will help address providers’ and patients’ needs, Royal Philips CMO Carla Perón explained in an interview with In Vivo.


Crossject Tackles Needle Phobia In Emergency Settings

 

Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second

Teva CEO Francis Urges UK To ‘Wake Up And Understand’ Life Sciences Potential

 
• By 

The potential of the UK’s life sciences sector continues to be critically misunderstood and should be the cornerstone of both society and the economy, according to Teva’s CEO Richard Francis.  

Skye Biosciences — Advancing Nimacimab In The Anti-Obesity Market

 

Punit Dhillon, CEO of Skye Bioscience, tells In Vivo about the advancement of nimacimab as a weight loss mechanism within the growing space of anti-obesity therapeutics

Arrowhead Moving Into Commercial Territory

 
• By 

Christopher Anzalone is spearheading Arrowhead Pharmaceuticals' transformation from a development-focused to a commercial-stage biotech. The CEO touts an “almost plug and play” platform, a derisked development strategy and a busy pipeline with vast potential.